Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Olodanrigan. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGTR2 known ✓ | P50052 | 19/20 | 1.00 |
| ▸ | AGTR1 | P30556 | 2/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Olodanrigan SCHEMBL421411 | 1.00 | AGTR2 (1.00) | AGTR2AGTR1 | |
| Olodanrigan SCHEMBL8964136 | 1.00 | AGTR2 (1.00) | AGTR2AGTR1 | |
| Olodanrigan SCHEMBL29394365 | 1.00 | AGTR2 (1.00) | AGTR2AGTR1 | |
| SCHEMBL8964206 | 0.94 | AGTR2 (1.00) | AGTR2AGTR1 | |
| SCHEMBL3516607 | 0.94 | AGTR2 (1.00) | AGTR2AGTR1 | |
| SCHEMBL8964101 | 0.94 | AGTR2 (1.00) | AGTR2AGTR1 | |
| SCHEMBL3514261 | 0.94 | AGTR2 (0.88) | AGTR2AGTR1 | |
| SCHEMBL3519228 | 0.94 | AGTR2 (1.00) | AGTR2AGTR1 | |
| SCHEMBL3516610 | 0.94 | AGTR2 (0.88) | AGTR2AGTR1 | |
| SCHEMBL3517015 | 0.92 | AGTR2 (0.87) | AGTR2AGTR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160052925-A1 | METHOD OF TREATMENT OR PROPHYLAXIS INFTAMMATORY PAIN | NOVARTIS AG (CH) | 2016-02-25 | — | — | US | claimed |
| EP-2525795-B1 | METHODS AND COMPOSITIONS FOR IMPROVED NERVE CONDUCTION VELOCITY | SPINIFEX PHARM PTY LTD (AU) | 2015-10-21 | — | — | EP | claimed |
| US-9095587-B2 | Methods and compositions for improved nerve conduction velocity | SPINIFEX PHARMACEUTICALS PTY LTD (AU) | 2015-08-04 | — | — | US | claimed |
| US-8551950-B2 | Method of treatment or prophylaxis of inflammatory pain | SPINIFEX PHARMACEUTICALS PTY LTD (AU) | 2013-10-08 | — | — | US | claimed |
| US-20130131103-A1 | Methods and Compositions For Improved Nerve Conduction Velocity | NOVARTIS AG (CH) | 2013-05-23 | — | — | US | claimed |
| US-8404686-B2 | Method of treatment or prophylaxis | SPINIFEX PHARMACEUTICALS PTY LTD (AU) | 2013-03-26 | — | — | US | claimed |
| US-20120004259-A1 | METHOD OF TREATMENT OR PROPHYLAXIS | SPINIFEX PHARMACEUTICALS, PTY LTD (AU) | 2012-01-05 | — | — | US | claimed |
| WO-2011088504-A1 | METHODS AND COMPOSITIONS FOR IMPROVED NERVE CONDUCTION VELOCITY | SPINIFEX PHARMACEUTICALS PTY LTD (AU) | 2011-07-28 | — | — | WO | claimed |
| US-7795275-B2 | Method of treatment or prophylaxis | UNIQUEST PTY LIMITED (AU) | 2010-09-14 | — | — | US | claimed |
| EP-0641326-A1 | SUBSTITUTED 1,2,3,4-TETRAHYDROISOQUINOLINES WITH ANGIOTENSIN II RECEPTOR ANTAGONIST PROPERTIES | WARNER-LAMBERT COMPANY (US) | 1995-03-08 | — | — | EP | claimed |
| WO-1993023378-A1 | SUBSTITUTED 1,2,3,4-TETRAHYDROISOQUINOLINES WITH ANGIOTENSIN II RECEPTOR ANTAGONIST PROPERTIES | WARNER-LAMBERT COMPANY (US) | 1993-11-25 | — | — | WO | claimed |
| US-5246943-A | Substituted 1,2,3,4-tetahydroisoquinolines with angiotensin II receptor antagonist properties | WARNER-LAMBERT COMPANY (US) | 1993-09-21 | — | — | US | claimed |
| US-20230242522-A1 | SALT OF TETRAHYDROISOQUINOLINE DERIVATIVE, PREPARATION METHOD THEREFOR, AND MEDICAL USE THEREOF | ZHEJIANG HISUN PHARMACEUTICAL CO., LTD. (CN) | 2023-08-03 | — | — | US | disclosed |
| US-20230242522-A1 | SALT OF TETRAHYDROISOQUINOLINE DERIVATIVE, PREPARATION METHOD THEREFOR, AND MEDICAL USE THEREOF | ZHEJIANG HISUN PHARMACEUTICAL CO., LTD. (CN) | 2023-08-03 | — | — | US | disclosed |
| EP-4177253-A1 | TETRAHYDROISOQUINOLINE DERIVATIVE, PREPARATION METHOD THEREFOR, AND MEDICAL USE THEREOF | Zhejiang Hisun Pharmaceutical Co., Ltd. (CN) | 2023-05-10 | — | — | EP | disclosed |
| EP-4096648-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF HEMANGIOMA | Gillies Mcindoe Research Institute (NZ) | 2022-12-07 | — | — | EP | disclosed |
| EP-0641326-A1 | SUBSTITUTED 1,2,3,4-TETRAHYDROISOQUINOLINES WITH ANGIOTENSIN II RECEPTOR ANTAGONIST PROPERTIES | WARNER-LAMBERT COMPANY (US) | 1995-03-08 | — | — | EP | disclosed |
| US-5350757-A | Treatment of vascular restenosis, nervous system disorders and cognition enhancement | WARNER-LAMBERT COMPANY (US) | 1994-09-27 | — | — | US | disclosed |
| WO-1993023378-A1 | SUBSTITUTED 1,2,3,4-TETRAHYDROISOQUINOLINES WITH ANGIOTENSIN II RECEPTOR ANTAGONIST PROPERTIES | WARNER-LAMBERT COMPANY (US) | 1993-11-25 | — | — | WO | disclosed |
| US-5246943-A | Substituted 1,2,3,4-tetahydroisoquinolines with angiotensin II receptor antagonist properties | WARNER-LAMBERT COMPANY (US) | 1993-09-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130131103-A1 | Methods and Compositions For Improved Nerve Conduction Velocity | GAP43, CHRNB3, CHRNB4 | AGTR2 6/4885AGTR1 7/4885 |
| US-20230242522-A1 | SALT OF TETRAHYDROISOQUINOLINE DERIVATIVE, PREPARATION METHOD THEREFOR, AND MEDICAL USE THEREOF | AGTR2, AGTR1, SLC5A11 | AGTR2 1/4885AGTR1 2/4885 |
| US-20160052925-A1 | METHOD OF TREATMENT OR PROPHYLAXIS INFTAMMATORY PAIN | AGTR2, AGTR1, BDKRB2 | AGTR2 1/4885AGTR1 2/4885 |
| US-20120004259-A1 | METHOD OF TREATMENT OR PROPHYLAXIS | AGTR2, AGTR1, NTSR2 | AGTR2 1/4885AGTR1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.